Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treatedwith cediranib in combinationwith chemoradiation

Oncologist

Volumn 19, Issue 1, 2014, Pages 75-81

  Pinho, Marco C ^a   Polaskova, Pavlina ^a   Kalpathy Cramer, Jayashree ^a   Jennings, Dominique ^a   Emblem, Kyrre E ^a,b   Jain, Rakesh K ^a   Rosen, Bruce R ^a   Wen, Patrick Y ^c   Sorensen, A Gregory ^a   Batchelor, Tracy T ^a   Gerstner, Elizabeth R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Cediranib; Glioblastoma; Pseudoprogression; Vascular endothelial growth factor

Indexed keywords

CEDIRANIB; GLIOBLASTOMA; PSEUDOPROGRESSION; VASCULAR ENDOTHELIAL GROWTH FACTOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; DACARBAZINE; DISEASE PROGRESSION; FEMALE; GLIOBLASTOMA; HUMANS; INCIDENCE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; QUINAZOLINES; YOUNG ADULT;

EID: 84892601371     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0101     Document Type: Article

References (47)

1. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
2. Wen PY, Macdonald DR, Reardon DA et al. Updated response assessment criteria for highgrade gliomas: Response assessment in neurooncology working group. J Clin Oncol 2010; 28: 1963-1972.
3. Gerstner ER, Batchelor TT. Imaging and response criteria in gliomas. Curr Opin Oncol 2010; 22: 598-603.
4. Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008; 26: 2192-2197.
5. Fink J, Born D, Chamberlain MC. Pseudoprogression: Relevance with respect to treatment of high-grade gliomas. Curr Treat Options Oncol 2011; 12: 240-252.
6. Hoffman WF, Levin VA, Wilson CB. Evaluation of malignant glioma patients during the postirradiation period. J Neurosurg 1979; 50: 624-628.
7. de Wit MC, de Bruin HG, Eijkenboom W et al. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 2004; 63: 535-537.
8. Levin VA, Crafts DC, Norman DM et al. Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. J Neurosurg 1977; 47: 329-335.
9. Chamberlain MC, Glantz MJ, Chalmers L et al. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. JNeurooncol 2007; 82: 81-83.
10. Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008; 113: 405-410.
11. Roldán GB, Scott JN, McIntyre JB et al. Population-based study of pseudoprogression after chemoradiotherapy in GBM. Can J Neurol Sci 2009; 36: 617-622.
12. Batchelor TT, Sorensen AG, di Tomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11: 83-95.
13. Norden AD, Drappatz J, Wen PY. Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 2009; 5: 610-620.
14. Chamberlain MC. Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas. Cancer 2010; 116: 3988-3999.
15. Lai A, Tran A, Nghiemphu PL et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2011; 29: 142-148.
16. Vredenburgh JJ, Desjardins A, ReardonDAet al. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res 2011; 17: 4119-4124.
17. Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
18. Jain RK, di Tomaso E, Duda DG et al. Angiogenesis in brain tumours. Nat Rev Neurosci 2007; 8: 610-622.
19. Batchelor TT, Gerstner ER, Emblem KE et al. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci USA 2013; 110: 19059-19064.
20. Benner T, Wisco JJ, van der Kouwe AJ et al. Comparison of manual and automatic section positioning of brain MR images. Radiology 2006; 239: 246-254.
21. Brandsma D, van den Bent MJ. Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol 2009; 22: 633-638.
22. Clarke JL, Chang S. Pseudoprogression and pseudoresponse: Challenges in brain tumor imaging. Curr Neurol Neurosci Rep 2009; 9: 241-246.
23. Jahangiri A, Aghi MK. Pseudoprogression and treatment effect. Neurosurg Clin N Am 2012; 23: 277-287, viii-ix.
24. Thompson EM, Frenkel EP, Neuwelt EA. The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology 2011; 76: 87-93.
25. Chamberlain MC. The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology 2011; 77: 803; author reply 803-804.
26. FDA approval for bevacizumab: Second-line treatment of glioblastoma. Available at http://www. cancer. gov/cancertopics/druginfo/fda-bevacizumab# Anchor-Glioblastoma. Accessed October 13, 2012.
27. Beal K, Abrey LE, Gutin PH. Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: Analysis of single-agent and combined modality approaches. Radiat Oncol 2011; 6: 2.
28. Narayana A, Kelly P, Golfinos J et al. Antiangiogenic therapy using bevacizumab in recurrent highgrade glioma: Impact on local control and patient survival. J Neurosurg 2009; 110: 173-180.
29. Norden AD, Young GS, Setayesh K et al. Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence. Neurology 2008; 70: 779-787.
30. Zuniga RM, Torcuator R, Jain R et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 2009; 91: 329-336.
31. Vredenburgh JJ, Desjardins A, Herndon JE II et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007; 13: 1253-1259.
32. Vredenburgh JJ, Desjardins A, Herndon JE II et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25: 4722-4729.
33. Furuse M, Kawabata S, Kuroiwa T et al. Repeated treatments with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: A report of 2 cases. J Neurooncol 2011; 102: 471-475.
34. Gonzalez J, Kumar AJ, Conrad CA et al. Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 2007; 67: 323-326.
35. Levin VA, Bidaut L, Hou P et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 2011; 79: 1487-1495.
36. Matuschek C, Bölke E, Nawatny J et al. Bevacizumab as a treatment option for radiation-induced cerebral necrosis. Strahlenther Onkol 2011; 187: 135-139.
37. Wedge SR, Kendrew J, Hennequin LF et al. AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005; 65: 4389-4400.
38. Narayana A, Gruber D, Kunnakkat S et al. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J Neurosurg 2012; 116: 341-345.
39. Nghiemphu PL, Liu W, Lee Y et al. Bevacizumab and chemotherapy for recurrent glioblastoma: A single-institution experience. Neurology 2009; 72: 1217-1222.
40. Zhang G, Huang S, Wang Z. A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme. J Clin Neurosci 2012; 19: 1636-1640.
41. Batchelor TT, Mulholland P, Neyns B et al. PhaseIII randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 2013; 31: 3212-3218.
42. Sorensen AG, Emblem KE, Polaskova P et al. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res 2012; 72: 402-407.
43. Huang S, Stylianopoulos T, Duda DG et al. Letter to the editor-benefits of vascular normalization are dose and time dependent. Cancer Res 2013 (in press).
44. Vredenburgh JJ, Desjardins A, Kirkpatrick JP et al. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2012; 82: 58-66.
45. Gilbert MR, Wang M, Aldape KD et al. RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (DD) schedule in newly diagnosed glioblastoma (GBM). J Clin Oncol 2011; 29 (suppl): 2006a.
46. Malmström A, Grønberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: The Nordic randomised, phase 3 trial. Lancet Oncol 2012; 13: 916-926.
47. Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: The NOA-08 randomised, phase 3 trial. Lancet Oncol 2012; 13: 707-715.